Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DermTech receives melanoma patent
The patent claims the use of DermTech’s ‘tape stripping’ technology for the purposes of detecting, staging and monitoring melanoma. The methods claimed in the patent focus on the
The patent claims the use of DermTech’s ‘tape stripping’ technology for the purposes of detecting, staging and monitoring melanoma. The methods claimed in the patent focus on the
MedaSorb has initiated its first clinical site and will be enrolling up to a total of nine sites for the European study. MedaSorb estimates the study will take
Under the terms of the agreement, PerkinElmer will acquire Pediatrix’s metabolic screening laboratory and its StepOne newborn screening product that is capable of analyzing more than 50 inherited
The drug master file (DMF) is a submission to the FDA that will be used to provide confidential detailed information about facilities, processes, or articles used in the
Galapagos will receive E3 million upfront payment from Lilly. Contingent on achieving certain milestones, Galapagos is eligible for each target program to receive up to E88 million in
The new alliance will focus on the evaluation and further development of a radioligand discovered by AstraZeneca. This radioligand is a molecule that binds to amyloid plaque protein
Under the terms of the agreement this will trigger a major milestone payment from Meldex International in February 2008. Kerry Gray, president and CEO of Uluru, said: “I
Under the terms of the agreement, InSite grants exclusive rights to Shin Poong to commercialize AzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis treatment in Korea. Shin Poong
The new drug application (NDA) is supported by data from three open-label, multi-center, randomized phase III efficacy and safety clinical studies and a fourth phase III safety study.
The objective of this trial is to evaluate the anti-tumor activity of IPI-504 in patients with non-small cell lung cancer (NSCLC). Initially, the phase II portion of the